STOCK TITAN

Aimei Health gets deal deadline extension to Dec. 6, 2027

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Aimei Health Technology Co., Ltd. (AFJK) received shareholder approval to extend its business-combination deadline from December 6, 2026, to December 6, 2027, extending the permitted period from up to 36 months to up to 48 months from its IPO. The Articles amendment took effect November 10, 2026; the related Trust Agreement amendment is dated November 19, 2026. The required trust deposit for each monthly extension remains the lesser of $80,000 for all outstanding Public Shares and $0.033 for each outstanding Public Share. The Article and Trust Agreement proposals each received 2,757,268 votes for, 5,377 against and 16 abstentions.

Holders of 841,629 Public Shares exercised redemption rights for cash at approximately $12.33 per share, for approximately $10,377,384 in total. After payment, the Trust Account will have approximately $2,450,031, and the company will have 2,324,703 ordinary shares outstanding.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.03 Material Modification to Rights of Security Holders Securities
A change was made that materially affects the rights of existing shareholders (e.g., dividend rights, voting rights).
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Business-combination period up to 48 months from IPO Extended from up to 36 months; deadline is December 6, 2027.
Public Shares with redemption rights exercised 841,629 shares Holders exercised rights for cash.
Redemption price approximately $12.33 per share Price for Public Shares subject to exercised redemption rights.
Aggregate redemption amount approximately $10,377,384 Cash amount associated with the exercised redemption rights.
Trust Account balance approximately $2,450,031 Balance after redemption payments.
Ordinary shares outstanding 2,324,703 shares Amount after redemption payments.
Monthly extension deposit lesser of $80,000 for all outstanding Public Shares and $0.033 for each outstanding Public Share Required amount for each monthly extension.
Ordinary shares issued and outstanding 3,166,332 shares As of the October 2, 2026 record date.
initial business combination financial
"consummate its initial business combination"
An initial business combination is the deal in which a special-purpose acquisition company (SPAC) merges with or acquires an operating business to bring that business onto public markets. Think of the SPAC as an empty shell that raises money from investors, then uses that cash to buy a private company—this transaction turns the private company into a public one and often changes its ownership, valuation, and access to capital, so investors should watch for shifts in risk, future growth prospects, and shareholder rights.
Trust Account financial
"trust account managed by the Trustee"
A trust account is a special bank or brokerage account where assets are held and managed by a designated person or firm (the trustee) for the benefit of another person or group (the beneficiary). It matters to investors because it separates assets from personal or corporate funds, can protect assets, control how and when money is used, and may affect tax or legal rights—think of it as a locked drawer opened only under agreed rules.
Public Shares financial
"ordinary shares sold in the IPO (the “Public Shares”)"
broker non-votes regulatory
"There were 79,881 broker non-votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
special resolution regulatory
"approved, as a special resolution"
A special resolution is a formal shareholder vote that requires a higher-than-normal majority—typically around three-quarters—to approve major corporate changes, such as altering the company’s governing rules, selling the business, or winding it up. It matters to investors because it signals decisive, potentially value-altering actions that cannot be passed by a simple majority; think of it as needing extra votes to change the rules of a club, so minority interests are harder to override.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What business-combination deadline did AFJK shareholders approve?

Shareholders approved an extension to December 6, 2027, replacing the prior December 6, 2026 deadline. The Articles amendment took effect on November 10, 2026.

How many AFJK Public Shares had holders elected to redeem, and at what price?

Holders exercised redemption rights for 841,629 Public Shares at approximately $12.33 per share, totaling approximately $10,377,384. After payment, the Trust Account will have approximately $2,450,031.

How much must AFJK deposit for each monthly extension?

For each monthly extension, the required amount remains the lesser of $80,000 for all outstanding Public Shares and $0.033 for each outstanding Public Share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
false --12-31 0001979005 0001979005 2026-11-10 2026-11-10 0001979005 AFJK:OrdinarySharesParValue0.0001PerShareMember 2026-11-10 2026-11-10 0001979005 AFJK:RightsExchangeableIntoOnefifthOfOneOrdinaryShareMember 2026-11-10 2026-11-10 0001979005 AFJK:UnitsEachConsistingOfOneOrdinaryShareAndOneRightMember 2026-11-10 2026-11-10 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

November 10, 2026

Date of Report (Date of earliest event reported)

 

AIMEI HEALTH TECHNOLOGY CO., LTD

(Exact Name of Registrant as Specified in its Charter)

 

Cayman Islands   001-41880   N/A

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(I.R.S. Employer

Identification No.)

 

10 East 53rd Street, Suite 3001

New York, NY

  10022
(Address of Principal Executive Offices)   (Zip Code)

 

86-13758131392

Registrant’s telephone number, including area code

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each Class   Trading Symbol(s)   Name of each exchange on which registered
Ordinary Shares, par value $0.0001 per share   AFJK   The Nasdaq Stock Market LLC
Rights, exchangeable into one-fifth of one Ordinary Share   AFJKR   The Nasdaq Stock Market LLC
Units, each consisting of one Ordinary Share and one Right   AFJKU   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 1.01. Entry into a Material Definitive Agreement.

 

Trust Agreement Amendment

 

As approved by its shareholders at the Extraordinary General Meeting (defined below), Aimei Health Technology Co., Ltd (the “Company”) entered into a third amendment dated November 19, 2026 (the “Trust Agreement Amendment”) to the Investment Management Trust Agreement, dated December 1, 2023, as amended (the “Trust Agreement”), with Continental Stock Transfer & Trust Company, as trustee (“Trustee”). Pursuant to the Trust Agreement Amendment, the period within which the Company may consummate its initial business combination is extended from up to 36 months from the date of the Company’s initial public offering (“IPO”) (namely, December 6, 2026) to up to 48 months from the date of the IPO (namely, December 6, 2027) (the “Extension”). The amount of funds required to be deposited into the trust account managed by the Trustee (the “Trust Account”) for each monthly extension remains the lesser of (i) $80,000 for all outstanding ordinary shares sold in the IPO (the “Public Shares”) and (ii) $0.033 for each outstanding Public Share.

 

The Trust Agreement Amendment is filed as Exhibit 10.1 hereto, which is incorporated herein by reference.

 

Item 3.03. Material Modification to Rights of Security Holders.

 

The information disclosed in Item 5.07 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03 to the extent required herein.

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

Pursuant to the results of the Extraordinary General Meeting, Article 35.2 of the Amended and Restated Articles of Association of the Company, as in effect immediately prior to the Extraordinary General Meeting, was amended and restated to extend the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering (namely, December 6, 2026) to 48 months from the date of the Company’s initial public offering (namely, December 6, 2027). In accordance with Cayman Islands law, the Company will forward a copy of the special resolution approving the Article Amendment Proposal to the Cayman Islands Registrar of Companies (in the form attached as Exhibit 3.1). Such exhibit is incorporated by reference into this Item 5.03. The information disclosed in Item 5.07 of this Current Report on Form 8-K is incorporated by reference into this Item 5.03 to the extent required herein.

 

Under Cayman Islands law, the amendment to the Articles took effect upon approval of the Article Amendment Proposal on November 10, 2026.

 

 
 

 

Item 5.07. Submission of Matters to a Vote of Security Holders.

 

On November 10, 2026, the Company held its previously announced extraordinary general meeting of shareholders of the Company (the “Extraordinary General Meeting”) virtually online at https://www.virtualshareholdermeeting.com/AFJKU2026, pursuant to due notice. The board of directors of the Company fixed the close of business on October 2, 2026 as the record date for the determination of shareholders entitled to notice of and to vote at the Extraordinary General Meeting or at any adjournment thereof (“Record Date”). On the Record Date, the Company had 3,166,332 ordinary shares issued and outstanding and holders of such shares were entitled to notice of and to vote at the Extraordinary General Meeting. At the Extraordinary General Meeting, holders of the Company’s outstanding ordinary shares in attendance (represented in person or by proxy) voted on four proposals presented, the Article Amendment Proposal, the Trust Agreement Amendment Proposal, the Auditor Appointment Proposal, and the Adjournment Proposal, each as described in the proxy statement dated October 19, 2026 (the “EGM Proxy Statement”). The shareholders represented in person or by proxy and entitled to vote at the Extraordinary General Meeting cast their votes as described below.

 

Capitalized terms used but not defined herein have the meaning given to them in the EGM Proxy Statement.

 

Proposal 1 - Article Amendment Proposal

 

The holders of the outstanding ordinary shares of the Company in attendance (represented in person or by proxy) and entitled to vote at the Extraordinary General Meeting approved, as a special resolution, the proposal to amend and restate Article 35.2 of the Amended and Restated Articles of Association of the Company currently in effect (the “Articles”), to extend the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering (namely, December 6, 2026) to 48 months from the date of the Company’s initial public offering (namely, December 6, 2027). The following is a tabulation of the voting results:

 

Ordinary shares:

 

   Votes For   Votes Against   Abstentions 
Number of outstanding ordinary shares voted:   2,757,268    5,377    16 

 

There were 79,881 broker non-votes with respect to the Article Amendment Proposal. Broker non-votes are counted for quorum purposes.

 

Proposal 2 - Trust Agreement Amendment Proposal

 

The holders of the outstanding ordinary shares of the Company in attendance (represented in person or by proxy) and entitled to vote at the Extraordinary General Meeting approved, as an ordinary resolution, the proposal to amend the Investment Management Trust Agreement dated December 1, 2023, as amended, entered into by and between Continental Stock Transfer & Trust Company, as trustee, and the Company, to reflect the extension of the date by which the Company has to consummate a business combination from 36 months from the date of the Company’s initial public offering to 48 months from the date of the Company’s initial public offering. The following is a tabulation of the voting results:

 

Ordinary shares:

 

   Votes For   Votes Against   Abstentions 
Number of outstanding ordinary shares voted:   2,757,268    5,377    16 

 

There were 79,881 broker non-votes with respect to the Trust Agreement Amendment Proposal.

 

 
 

 

Proposal 3 - Auditor Appointment Proposal

 

The holders of the outstanding ordinary shares of the Company in attendance (represented in person or by proxy) and entitled to vote at the Extraordinary General Meeting approved, as an ordinary resolution, the engagement of MaloneBailey, LLP to serve as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The following is a tabulation of the voting results:

 

Ordinary shares:

 

   Votes For   Votes Against   Abstentions 
Number of outstanding ordinary shares voted:   2,840,119    1,961    462 

 

There were no broker non-votes with respect to the Auditor Appointment Proposal.

 

Proposal 4 - Adjournment Proposal

 

The holders of the outstanding ordinary shares of the Company in attendance (represented in person or by proxy) and entitled to vote at the Extraordinary General Meeting approved the proposal to direct the chairman of the Extraordinary General Meeting to adjourn the Extraordinary General Meeting to a later date or dates to permit further solicitation of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Article Amendment Proposal, the Trust Agreement Amendment Proposal, or the Auditor Appointment Proposal, to be determined by the chairman of the Extraordinary General Meeting. The following is a tabulation of the voting results:

 

Ordinary shares:

 

   Votes For   Votes Against   Abstentions 
Number of outstanding ordinary shares voted:   2,834,906    7,174    462 

 

There were no broker non-votes with respect to the Adjournment Proposal.

 

Item 8.01. Other Events.

 

In connection with the approval of the Article Amendment Proposal at the Extraordinary General Meeting, and as of the reporting date, holders of 841,629 Public Shares exercised their right to redeem those shares for cash at an approximate price of $12.33 per share, for an aggregate of approximately $10,377,384. Following the payment of the redemptions, the Trust Account will have a balance of approximately $2,450,031 and the Company will have 2,324,703 ordinary shares outstanding.

 

No Offer or Solicitation

 

This Current Report on Form 8-K shall not constitute a solicitation of a proxy, consent, or authorization with respect to any securities or in respect of any business combination. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or an exemption therefrom.

 

Forward-Looking Statements

 

This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. These forward-looking statements and factors that may cause such differences include, without limitation, uncertainties relating to our ability to complete an initial Business Combination and other risks and uncertainties indicated from time to time in our filings with the SEC, including under the caption “Risk Factors” in the reports we file with the SEC. The Company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

 

Item 9.01 Exhibits.

 

(d) Exhibits.

 

Exhibit No.   Description
3.1   Form of Director’s Certificate certifying the special resolution passed by the Company at the Extraordinary General Meeting 
10.1   Third Amendment to the Investment Management Trust Agreement, dated November 19, 2026, by and between Aimei Health Technology Co., Ltd and Continental Stock Transfer & Trust Company
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 19, 2026

 

  Aimei Health Technology Co., Ltd
     
  By: /s/ Junheng Xie
  Name: Junheng Xie
  Title: Chief Executive Officer

 

 

 

Filing Exhibits & Attachments

75 documents

Agreements & Contracts

Other Documents

Keep reading